ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5107ometendo-5107Research ArticleСтатьиArticlesДинамика массы тела у пациентас пролактинсекретирующей аденомой гипофизадо и после лечения каберголиномDinamika massy tela u patsientas prolaktinsekretiruyushchey adenomoy gipofizado i posle lecheniya kabergolinomGiniyatullinaE N-DzeranovaL K-RozhinskayaL Ya-GoncharovN P-DobrachevaA D-20091503200961№1 (2009)3739Copyright © Giniyatullina E.N., Dzeranova L.K., Rozhinskaya L.Y., Goncharov N.P., Dobracheva A.D., 20092009Giniyatullina E.N., Dzeranova L.K., Rozhinskaya L.Y., Goncharov N.P., Dobracheva A.D.Giniyatullina E.N., Dzeranova L.K., Rozhinskaya L.Y., Goncharov N.P., Dobracheva A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5107ReferencesДедов И.И., Мельниченко Г.А. Персистирующая галакторея-аменорея - М.: Медицина, 1985. - 253 с.Дедов И.И., Мельниченко Г.А. Персистирующая галакторея-аменорея - М.: Медицина, 1985. - 253 с.Романцова Т.И. Особенности клинической симптоматики, диагностики и лечения синдрома гиперпролактинемии у женщин. Автореферат. Дис. докт. мед.наук. -М. 2001.Романцова Т.И. Особенности клинической симптоматики, диагностики и лечения синдрома гиперпролактинемии у женщин. Автореферат. Дис. докт. мед.наук. -М. 2001.Baptista Т., Lacruz A., Meza Т., Contreras Q., Delgado C., Mejas M.A., Hernаndez L. Antipsychotic drugs and obesity: is prolactin involved? // Can J Psychiatry. - 2001. -Vol. 46. N 9. - P. 829-834.Baptista Т., Lacruz A., Meza Т., Contreras Q., Delgado C., Mejas M.A., Hernаndez L. Antipsychotic drugs and obesity: is prolactin involved? // Can J Psychiatry. - 2001. -Vol. 46. N 9. - P. 829-834.Brandebourg Т., Hugo E. Adipocyte prolactin: regulation of release and putative functions. Diabetes, Obesity and Metabolism, 9, 2007, 464-476.Brandebourg Т., Hugo E. Adipocyte prolactin: regulation of release and putative functions. Diabetes, Obesity and Metabolism, 9, 2007, 464-476.Burstyn P.G., Horrobin D.F., Muiruri K. Effects of a high fat diet and of intravenous infusions of cholesterol on arterial pressure in rabbits. Br J Exp Pathol 1972 Jun;53(3): 258-64.Burstyn P.G., Horrobin D.F., Muiruri K. Effects of a high fat diet and of intravenous infusions of cholesterol on arterial pressure in rabbits. Br J Exp Pathol 1972 Jun;53(3): 258-64.Cincotta A. H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 1996, 19, 667-70.Cincotta A. H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 1996, 19, 667-70.Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N EngfJ Med 2003; 349: 2023-33.Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N EngfJ Med 2003; 349: 2023-33.Colao A., Gillam M.P., Molitch M.E., Lombardi G. Advances in the Treatment of Prolactinomas Endocrine Reviews 2006, 27J5): 485-534.Colao A., Gillam M.P., Molitch M.E., Lombardi G. Advances in the Treatment of Prolactinomas Endocrine Reviews 2006, 27J5): 485-534.Gillam M.P., Middler S., Freed D.J., Molitch ME 2002. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451.Gillam M.P., Middler S., Freed D.J., Molitch ME 2002. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451.Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels Clin Endocrinol 1998, 48, 547-53.Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels Clin Endocrinol 1998, 48, 547-53.Herring N., Szmigielski C. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology (2009) 70, 104-108.Herring N., Szmigielski C. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology (2009) 70, 104-108.Kamath V., Jones C.N., Yip J.C. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women Diabetes Care 1997, 20, 1697-701.Kamath V., Jones C.N., Yip J.C. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women Diabetes Care 1997, 20, 1697-701.Keshavan G. Bina, Anthony H. Cincotta. Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice. Neuroendocrinology 2000; 71: 68-78.Keshavan G. Bina, Anthony H. Cincotta. Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice. Neuroendocrinology 2000; 71: 68-78.Korner J. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obesity Research (2003) 11, 31 1-312; doi: 10.1038/oby. 2003.46.Korner J. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obesity Research (2003) 11, 31 1-312; doi: 10.1038/oby. 2003.46.Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology. 2001 Nov;142(11):4880-90.Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology. 2001 Nov;142(11):4880-90.McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996, 137:5723-5726.McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996, 137:5723-5726.Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. // Clin Endocrinol (Oxf). -1982.- Vol. 16. N. 4. - P. 383-390.Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. // Clin Endocrinol (Oxf). -1982.- Vol. 16. N. 4. - P. 383-390.Pijl H., Ohashi S., Matsuda M. Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23,1154-1161.Pijl H., Ohashi S., Matsuda M. Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23,1154-1161.Prior J.C., Cox T.A., Fairholm D., Kostashuk E., Nugent R. 1987 Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391-394.Prior J.C., Cox T.A., Fairholm D., Kostashuk E., Nugent R. 1987 Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391-394.Weaver J.U., Noonan K., Kopelman P.G., Coste M. Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 1990 May; 32(5): 641-6.Weaver J.U., Noonan K., Kopelman P.G., Coste M. Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 1990 May; 32(5): 641-6.Zamorano P.L. et al. 1997 Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat. Neuroendocrinology 65: 223-228.Zamorano P.L. et al. 1997 Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat. Neuroendocrinology 65: 223-228.
The authors declare that there are no conflicts of interest present.